Financial

CLINUVEL
Posted by CLINUVEL
May 20, 2022

Notice of initial substantial holder

Melbourne, Australia, 20 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 12, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 12 May 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 10, 2022

CLINUVEL progresses vitiligo study

CLINUVEL today announced that it will start treatment of vitiligo patients with...

Read More
CLINUVEL
Posted by CLINUVEL
May 6, 2022

Notification regarding unquoted securities

Melbourne, Australia, 6 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
April 29, 2022

CEO letter

For the benefit of the 2.5% recently joined shareholders, I distinguish CLINUVEL’s...

Read More
CLINUVEL
Posted by CLINUVEL
April 28, 2022

Appendix 4C & Activity Report

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...

Read More
CLINUVEL
Posted by CLINUVEL
April 27, 2022

Notice of ceasing to be a substantial holder

Melbourne, Australia, 27 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
April 7, 2022

Initial Director’s Interest Notice

Melbourne, Australia, 7 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
April 4, 2022

CLINUVEL appoints new Non-Executive Director

Melbourne, Australia, 04 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
March 23, 2022

Change of Director's Interest Notice

Melbourne, Australia, 23 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
March 2, 2022

Change of Director's Interest Notice

Melbourne, Australia, 02 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
Lachlan Hay
Posted by Lachlan Hay
February 28, 2022

CEO letter

On 24 February, the world plunged into instability, initiated by delusional warfare...

Read More
CLINUVEL
Posted by CLINUVEL
February 23, 2022

CLINUVEL Reports Record December Half Year Operating Profit

Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
February 23, 2022

Appendix 4D - ASX Listing Rule 4.2A.3 Half Yearly Report

Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
February 16, 2022

Financial Results Half Year Ended, 31 December 2021

CLINUVEL PHARMACEUTICALS LTD announced today the financial results for the half year...

Read More